Charles Schwab
MNPR icon

Charles Schwab’s Monopar Therapeutics MNPR Stock Holding History

Charles Schwab’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
13,953
+1,395
+11% +$86.4K ﹤0.01% 2925
2026
Q1 		$688K Sell
12,558
-1,727
-12% -$104K ﹤0.01% 3009
2025
Q4 		$933K Buy
14,285
+2,488
+21% +$203K ﹤0.01% 2945
2025
Q3 		$963K Sell
11,797
-1,452
-11% -$64.9K ﹤0.01% 2962
2025
Q2 		$474K Buy
+13,249
New +$481K ﹤0.01% 3156

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Charles Schwab's MNPR Position: Q2 2026 in Review

Charles Schwab increased its Monopar Therapeutics (MNPR) stake by 11% in Q2 2026, buying an estimated $86.4K and bringing the position to 13,953 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

Charles Schwab first reported a position in MNPR in Q2 2025 and has held it in 5 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Charles Schwab held 13,953 shares of Monopar Therapeutics worth $1.29M as of Q2 2026.
  • Charles Schwab bought 1,395 Monopar Therapeutics shares in Q2 2026, an estimated $86.4K.
  • Monopar Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2925 holding.
  • Charles Schwab first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.